Page last updated: 2024-08-21

pyrazines and vx680

pyrazines has been researched along with vx680 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A	1
Hatano, Y; Iida, S; Ito, M; Iwamoto, K; Kitabayashi, A; Kume, M; Nara, M; Sawada, K; Tagawa, H; Takahashi, N; Teshima, K; Watanabe, A	1

Reviews

1 review(s) available for pyrazines and vx680

Article	Year
[Novel medical treatment modalities in hematology]. Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24 Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine	2008

Article

Year

[Novel medical treatment modalities in hematology].

Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008

Other Studies

1 other study(ies) available for pyrazines and vx680

Article	Year
Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PloS one, 2013, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Polycomb-Group Proteins; Primary Cell Culture; Pyrazines; Side-Population Cells; Signal Transduction; Syndecan-1; Ubiquitins	2013

Article

Year

Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.

PloS one, 2013, Volume: 8, Issue:3

Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Polycomb-Group Proteins; Primary Cell Culture; Pyrazines; Side-Population Cells; Signal Transduction; Syndecan-1; Ubiquitins

2013